Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients

May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of life (HRQoL) and did not worsen side effect burden, consistent with ADT alone.[1] These data are being presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8 (Abstract #5068).“Concern about side effects and their resulting burden on quality of life can be a barrier for patients when considering treatment options,” said Neeraj Agarwal, M.D., of the University of Utah Huntsman Cancer Institute, and the lead study investigator for TITAN.* “The significant long-term overall survival benefit we’ve seen demonstrated with ERLEADA, with no impact on quality of life as reported by patients, underscores the important role of this therapy in the treatment of advanced prostate cancer.” No significant differences in quality of life were observed between patients who received ERLEADA® plus ADT and patients who received placebo plus ADT.1 Ove...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news